Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 8NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 15Other hematologic neoplasm 14Lymphoid 13Gynecologic 10Genitourinary 7Dermatologic 7CNS 7Plasma cell 5Other solid neoplasm 4Gastrointestinal 4Thoracic 3Head & Neck 2Breast 2Tumor-Agnostic 1Myeloid 1Classical hematology 1

Conditions

Neoplasms 1

Interventions

Specimen Handling 19Biopsy 18Magnetic Resonance Spectroscopy 12Paclitaxel 9trastuzumab deruxtecan 4olaparib 4X-Rays 4Taxes 4nilotinib 3Radiotherapy 3Gemcitabine 3Cisplatin 3Carboplatin 3Bevacizumab 3trametinib 2talazoparib 2pembrolizumab 2omipalisib 2durvalumab 2copanlisib 2aldesleukin 2Vincristine 2Topotecan 2Phantoms, Imaging 2Leucovorin 2Immunoglobulin G 2Fluorouracil 2Doxorubicin 2Disulfides 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sirolimus × Tumor-Agnostic × Clear all
NCT00678769 2015-11-04

Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
72 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡